MétaCan
Menu
Back to cohort
Record W4311668626 · doi:10.1038/s41591-022-02102-9

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

2022· article· en· W4311668626 on OpenAlexaff
Orly Vardeny, James C. Fang, Akshay S. Desai, Pardeep S. Jhund, Brian Claggett, Muthiah Vaduganathan, Rudolf A. de Boer, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martínez, Mikhail Kosiborod, David L. DeMets, Eileen O’Meara, Shelley Zieroth, Josep Comín‐Colet, Jarosław Dróżdż, Chern‐En Chiang, Masafumi Kitakaze, Magnus Petersson, Daniel Lindholm, Anna Maria Langkilde, John J.V. McMurray, Scott D. Solomon

Bibliographic record

VenueNature Medicine · 2022
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsUniversity of ManitobaUniversité de MontréalSt. Boniface HospitalMontreal Heart Institute
FundersNational Heart, Lung, and Blood InstituteRelypsaNational Medical Research CouncilRespicardiaAmerican RegentVifor PharmaDaiichi-SankyoUniversity of GlasgowBayer HealthCarePfizerModernaImpulse DynamicsSarepta TherapeuticsIonis PharmaceuticalsNational Institutes of HealthRegeneron PharmaceuticalsSanofi PasteurKowa CompanyCelladon CorporationDefense Acquisition Program AdministrationBoston Scientific CorporationMedical Research CouncilVerily Life SciencesBrigham and Women's HospitalHeart Failure Society of AmericaEsperion TherapeuticsAlnylam PharmaceuticalsNovo NordiskMyoKardiaServierBayerGilead SciencesCytokineticsEli Lilly and CompanyBristol-Myers SquibbAstraZenecaAmgenSanofiAmerican Heart Association
KeywordsDapagliflozinEjection fractionHeart failureMedicineInternal medicineCardiologyFraction (chemistry)ChemistryDiabetes mellitusEndocrinology

Abstract

fetched live from OpenAlex

With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management of this growing population, categorized as heart failure with improved EF (HFimpEF), which has a high event rate and has been excluded from virtually all prior heart failure outcomes trials. In a prespecified analysis of the DELIVER trial ( NCT03619213 ), of a total of 6,263 participants with symptomatic heart failure and a left ventricular EF >40%, 1,151 (18%) had HFimpEF, defined as patients whose EF improved from ≤40% to >40%. Participants were randomized to 10 mg dapagliflozin or placebo daily and the primary outcome of the trial was a composite of cardiovascular death or worsening heart failure (heart failure hospitalization or an urgent heart failure visit). Participants with HFimpEF had similar event rates to those with an EF consistently >40%. In participants with HFimpEF, dapagliflozin reduced the primary composite outcome (hazard ratio (HR) = 0.74, 95% confidence interval (CI) = 0.56-0.97), first worsening heart failure events (HR = 0.78, 95% CI = 0.61-1.14), cardiovascular death (HR = 0.62, 95% CI = 0.41-0.96) and total worsening heart failure events (rate ratio = 0.68, 95% CI = 0.50-0.94) to a similar extent as for individuals with an EF consistently >40%. These data suggest that patients with HFimpEF who are symptomatic may benefit from the addition of a sodium/glucose cotransporter 2 inhibitor to previously instituted guideline-directed medical therapy to further reduce morbidity and mortality.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.154
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.261
Teacher spread0.252 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations67
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueNature MedicineSame topicDiabetes Treatment and ManagementFrench-language works237,207